Cognition Therapeutics, Inc. (CGTX)
NASDAQ: CGTX · Real-Time Price · USD
0.583
-0.026 (-4.33%)
At close: Feb 21, 2025, 4:00 PM
0.580
-0.003 (-0.51%)
After-hours: Feb 21, 2025, 7:38 PM EST
Cognition Therapeutics Employees
As of December 31, 2023, Cognition Therapeutics had 28 total employees, including 25 full-time and 3 part-time employees. The number of employees increased by 3 or 12.00% compared to the previous year.
Employees
28
Change (1Y)
3
Growth (1Y)
12.00%
Revenue / Employee
n/a
Profits / Employee
-$1,223,929
Market Cap
24.23M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 28 | 3 | 12.00% |
Dec 31, 2022 | 25 | 4 | 19.05% |
Dec 31, 2021 | 21 | 1 | 5.00% |
Dec 31, 2020 | 20 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
CGTX News
- 23 days ago - Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC - GlobeNewsWire
- 6 weeks ago - Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences - GlobeNewsWire
- 2 months ago - Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday? - Benzinga
- 2 months ago - Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - GlobeNewsWire
- 3 months ago - Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies - GlobeNewsWire
- 3 months ago - Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population - GlobeNewsWire
- 3 months ago - Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update - GlobeNewsWire
- 3 months ago - Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum - GlobeNewsWire